Abstract:We previously reported that spliceosome-mediated RNA trans-splicing (SMaRT), using recombinant adenoviral vectors expressing pre-trans-splicing molecules (PTMs), could partially restore cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel activity to polarized human DeltaF508 CF airway epithelia. Although these studies proved that SMaRT could correct CFTR mRNA defects, recombinant adenoviral infection from the basolateral surface was required because of inefficient infection from the apical membrane. Hence, applications of SMaRT technology for CF gene therapy require further testing with alternative, more clinically viable, vector systems. Furthermore, because recombinant adeno-associated virus (rAAV) vectors have packing limitations with respect to the size of the CFTR transgene insert, SMaRT correction of CFTR has the added attraction of a smaller transgene cassette. In the present study, we investigated whether rAAV vectors could effectively rescue CFTR chloride conductance in polarized human CF airway epithelial cells, using a SMaRT approach. AAV vectors were generated to carry a PTM engineered to bind intron 9 of CFTR pre-mRNA and then trans-splice the normal sequence for human CFTR exons 10-24 into the endogenous pre-mRNA. Human CF polarized airway epithelia were infected from the apical membrane with rAAV2 or rAAV5 CFTR-PTM vectors in the presence of proteasome-modulating agents (doxorubicin and N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal) to enhance transduction. Epithelia were then evaluated for cAMP-sensitive short-circuit currents 2 weeks postinfection. Levels of CFTR correction seen with rAAV2 (1.07 +/- 0.24 microA) and rAAV5 (0.90 +/- 0.20 microA) CFTR-PTM vectors were similar, representing conductance equivalent to 14.2 and 13.6% of that observed in non-CF human polarized epithelia, respectively. RT-PCR analysis demonstrated the existence of wild-type CFTR transcript in CFTR-PTM-corrected epithelia, whereas only DeltaF508 mRNA was detected in polarized cells infected with control rAAV LacZ-PTM vectors. These results provide evidence that rAAV vectors are capable of using SMaRT to correct CFTR function after apical infection of human CF airway epithelia. The ability of CFTR-PTM-mediated correction to maintain endogenous CFTR regulation of the transgene product may further improve the efficacy of gene therapy for CF.

Investigating Adverse Genomic and Regulatory Changes Caused by Replacement of the Full-length CFTR cDNA Using Cas9 and AAV

CRISPR-Cas9 Mediated Gene Correction of CFTR Mutations in Cystic Fibrosis: Evaluating Efficacy, Safety, and Long-Term Outcomes in Patient-Derived Lung Organoids

DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length CFTR cDNA in Airway Stem Cells

Efficient Gene Editing at Major CFTR Mutation Loci

CRISPR/Cas9 gene editing therapies for cystic fibrosis

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator

Spliceosome-Mediated Rna Trans-Splicing with Recombinant Adeno-Associated Virus Partially Restores Cystic Fibrosis Transmembrane Conductance Regulator Function to Polarized Human Cystic Fibrosis Airway Epithelial Cells

Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors

Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing

Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells

521. Spliceosome-Mediated RNA Trans-Splicing with Raav Partially Restores CFTR Function to Polarized Human CF Airway Epithelial Cells

Application of CRISPR gene editing technology in cystic fibrosis treatment

Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation

Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models

Disruption of the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Embryonic Stem Cells by Gene Targeting.

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells